Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years. Nogapendekin alfa inbakicept ...
Experts recommend removing the black box warning on vaginal estrogen, citing overstated risks and emphasizing its benefits for menopausal women. Data shows significant cardiovascular benefits of HRT ...
Daniel Spratt, MD, reviews how closely MMAI-predicted 10-year distant metastasis and prostate cancer–specific mortality tracked observed STAR-CAP outcomes, including among patients treated with ...
The minimally invasive surgical therapy is approved for the treatment of lower urinary tract symptoms secondary to BPH. The FDA has approved the Optilume BPH Catheter System for the treatment of lower ...
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years. Sandip M. Prasad, MD, MPhil, ...
This digital series features articles and videos with insights and expert viewpoints on PSMA-PET and the evolving imaging paradigm that is revolutionizing the diagnosis and treatment of patients with ...
Pastuszak discusses the evolving nature of understanding how testosterone therapy post-radiation for prostate cancer may beneficial or harmful to patients, and how to navigate the decision. Overall, a ...
Dr. Michael Lipkin discusses a recent study conducted at Duke University Hospital that found that a new single-use cystoscope demonstrated superior flexion and comparable optics to the reusable scopes ...
"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD. In this interview, Mark C.
The Edison System uses histotripsy, a non-invasive ultrasound technology, to treat kidney tumors without surgery, radiation, or systemic therapies. The #HOPE4KIDNEY trial enrolled 67 patients with non ...
"As urologists, we should be proactive and creative as we find new ways to attract, retain and train the next generation," writes Michael S. Cookson, MD, MMHC, FACS. The 2025 RAND-AAMC system-dynamics ...
Genomic biomarker testing aids in refining risk stratification and guiding treatment decisions for patients with intermediate-risk with prostate cancer. Many patients with favorable intermediate-risk ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results